QUOTED. 11 January. Peter Wrighton-Smith.
PerkinElmer has agreed to buy Oxford Iummunotec for $591m to add the UK company’s T-cell immunology expertise and proprietary tuberculosis testing technology to its line of infectious disease testing products. See what Oxford Immunotec’s CEO Peter Wrighton-Smith said about it here.
“Access to PerkinElmer’s global reach and automation experience will enable us to accelerate our growth journey and make a growing impact in the field of infectious disease.” – Peter Wrighton-Smith, CEO, Oxford Immunotec
Click here for a free trial of Medtech Insight